356 related articles for article (PubMed ID: 37256127)
1. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.
Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J
Front Immunol; 2023; 14():1189520. PubMed ID: 37256127
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
3. By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma.
Zhang P; Pei S; Gong Z; Feng Y; Zhang X; Yang F; Wang W
Front Immunol; 2023; 14():1115272. PubMed ID: 36776843
[TBL] [Abstract][Full Text] [Related]
4. Elaboration and validation of a prognostic signature associated with disulfidoptosis in lung adenocarcinoma, consolidated with integration of single-cell RNA sequencing and bulk RNA sequencing techniques.
He D; Tang H; Yang X; Liu X; Zhang Y; Shi J
Front Immunol; 2023; 14():1278496. PubMed ID: 37965333
[TBL] [Abstract][Full Text] [Related]
5. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract][Full Text] [Related]
6. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
8. Single-cell analysis reveals exosome-associated biomarkers for prognostic prediction and immunotherapy in lung adenocarcinoma.
Lin S; Zhou S; Han X; Yang Y; Zhou H; Chang X; Zhou Y; Ding Y; Lin H; Hu Q
Aging (Albany NY); 2023 Oct; 15(20):11508-11531. PubMed ID: 37878007
[TBL] [Abstract][Full Text] [Related]
9. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
10. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
12. The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma.
Zhang P; Pei S; Gong Z; Ren Q; Xie J; Liu H; Wang W
Front Endocrinol (Lausanne); 2023; 14():1154410. PubMed ID: 37033259
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing.
Song P; Li W; Guo L; Ying J; Gao S; He J
Front Immunol; 2022; 13():850745. PubMed ID: 35757748
[TBL] [Abstract][Full Text] [Related]
14. Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma.
Fan T; Lu J; Niu D; Zhang Y; Wang B; Zhang B; Zhang Z; He X; Peng N; Li B; Fang H; Gong Z; Zhang L
Front Immunol; 2022; 13():1046121. PubMed ID: 36483553
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a muscle failure index to predict prognosis and immunotherapy in lung adenocarcinoma through integrated analysis of bulk and single-cell RNA sequencing data.
Gu X; Cai L; Luo Z; Shi L; Peng Z; Sun Y; Chen J
Front Immunol; 2022; 13():1057088. PubMed ID: 36733390
[TBL] [Abstract][Full Text] [Related]
16. Validating a Macrophage Marker Gene Signature (MMGS) in Lung Adenocarcinoma Prognosis and Response to Immunotherapy.
Song P; Wusiman D; Li W; Guo L; Ying J; Gao S; He J
J Immunother; 2023 Jul-Aug 01; 46(6):205-215. PubMed ID: 37220007
[TBL] [Abstract][Full Text] [Related]
17. Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.
Huang L; Lou N; Xie T; Tang L; Han X; Shi Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3259-3277. PubMed ID: 37458771
[TBL] [Abstract][Full Text] [Related]
18. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
Sui P; Liu X; Zhong C; Sha Z
Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
[TBL] [Abstract][Full Text] [Related]
19. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
20. Single-cell and Bulk RNA-Seq reveal angiogenic heterogeneity and microenvironmental features to evaluate prognosis and therapeutic response in lung adenocarcinoma.
Tang L; Chen Z; Yang J; Li Q; Wang S; Mo T; Zeng W; Ding H; Pan S
Front Immunol; 2024; 15():1352893. PubMed ID: 38390340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
